(17078830), Q. X., (17078833), K. H., (17078836), X. M., (17078839), Y. W., (17078842), L. Z., (17078845), L. B., . . . (17078857), Q. C. (2025). Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.
Chicago-čujuhus (17. p.)(17078830), Qingsheng Xu, et al. Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. 2025.
MLA-čujuhus (9. p.)(17078830), Qingsheng Xu, et al. Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. 2025.
Muitte dárkkistit čujuhemiid riektatvuođa, ovdal go geavahat daid iežat deavsttas.